26 Feb 2018 I Orion's Financial Statement documents for 2017 are published, and include Financial Statements, the report of the Board of Directors and the Auditor's report.
|3/1/2018||Orion Corporation: Transfer of 112,961 own B shares on 1 March 2018|
|2/26/2018||Orion Group Financial Statement documents 2017 and Corporate Governance Statement published|
|2/7/2018||Notice to the annual general meeting of Orion Corporation|
|2/7/2018||Orion Group Financial Statement Release for 2017|
The product and service portfolio of Orion includes a variety of human pharmaceuticals, veterinary drugs, APIs, contract manufacturing and diagnostic tests.
Orion’s pharmaceutical innovations are created within its R&D organisation. The organisation employs top professionals in the field of drug molecule development and optimisation.
One key area of Orion's business is Critical Care. Our portfolio includes Simdax® for acute heart failure and Precedex® and Dexdor® for sedation. Read more about Orion's proprietary products and other human pharmaceuticals.